 |
 |

The Use of Chymotrypsin in the Treatment of Dendritic Keratitis
M. NOEL STOW, M.D.;
BEN H. JENKINS, M.D.
Arch Ophthalmol. 1961;66(1):61-63.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
Every ophthalmologist is familiar with the typical clinical appearance of dendritic ulcer of the cornea.
Since the first description of this virus infection of the cornea as a clinical entity by Horner1 in 1871, many forms of treatment have been tried. Among the therapeutic agents reported are alcohol, potassium iodide, hydrogen peroxide, silver nitrate, trichloracetic acid, epinephrine hydrochloride under a contact glass, alkalis, vaccination, curettage, paracentesis of the anterior chamber, ultraviolet light, x-rays, cobalt, strontium90, strong solution of iodine, and U.S.P. ether. Of all of the agents mentioned ether and strong solution of iodine have proved to be the most effective. However, both of these agents result in severe discomfort for the patient and they increase rather than decrease the possibility of corneal scarring.
The therapeutic application of chymotrypsin became possible after its crystallization in 1933. It is a proteolytic enzyme extracted from mammalian pancreas and is now
. . . [Full Text PDF of this Article]
Author Affiliations
Washington, D.C.; Newnan, Ga.
Footnotes
Submitted for publication April 6, 1961.
The lyophilized form of chymotrypsin used in this study was furnished by The Armour Pharmaceutical Company, Kankakee, Ill.
Presented at the Spring Alumni meeting of the Institute of Ophthalmology of the Columbia-Presbyterian Medical Center in New York City, April 21, 1961 (Dr. Stow).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|